A 5-HT2A antagonistic drug enhanced the release of dopamine in the striatum by decreasing the inhibitory effect of serotonin [24], indicating the potential role of serotonin and dopamine in schizophrenia pathogenesis. Here, HTR2A is linked to schizophrenia.